Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • World
  • Users
  • Groups
Skins
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (Darkly)
  • No Skin
Collapse
Brand Logo
  1. Home
  2. Uncategorized
  3. DATE: February 11, 2026 at 04:30AMSOURCE: STAT HEALTH TECH

DATE: February 11, 2026 at 04:30AMSOURCE: STAT HEALTH TECH

Scheduled Pinned Locked Moved Uncategorized
healthcarehealthtechhealthcaretechhealthtechnologmedgadget
1 Posts 1 Posters 0 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • Healthcare Tech RobotH This user is from outside of this forum
    Healthcare Tech RobotH This user is from outside of this forum
    Healthcare Tech Robot
    wrote last edited by
    #1

    DATE: February 11, 2026 at 04:30AM
    SOURCE: STAT HEALTH TECH

    TITLE: STAT+: Hims is in the crosshairs. Is a crackdown coming for compounding?

    URL: https://www.statnews.com/2026/02/11/hims-federal-scrutiny-impact-on-telehealth-compounding-pharmacies/?utm_campaign=rss

    In January, Novo Nordisk started selling a pill form of Wegovy, its previously injection-only weight loss medication. But for many Americans, it was old hat. They’d already been able to access semaglutide as a pill — and mints, and gummies, and even something that looks like a dissolvable breath strip — from compounding pharmacies and telehealth companies for more than a year. 

    And yet, when Hims & Hers — one of the largest telehealth platforms offering semaglutide — announced it would offer its own compounded version of the pill last week, the hammer came down swiftly.

    By Friday, the Food and Drug Administration said it would take “decisive steps” to restrict compounded GLP-1s from being mass marketed as similar to FDA-approved drugs, naming Hims specifically. The Department of Health and Human Services asked the Department of Justice to investigate the company for potential violations of the Food, Drug, and Cosmetic Act (FDCA). Over the weekend, Hims backed down, saying it would stop selling the pill, only to have Novo Nordisk file a patent infringement lawsuit on Monday. Hims stock has fallen 35% since Thursday.

    Continue to STAT+ to read the full story…

    URL: https://www.statnews.com/2026/02/11/hims-federal-scrutiny-impact-on-telehealth-compounding-pharmacies/?utm_campaign=rss

    -------------------------------------------------

    STAT News reports "from the frontiers of health and medicine".

    Learn more at https://www.statnews.com/category/health-tech/ .

    See also their complete Mastodon account at @STAT .

    This robot is NOT affiliated with STAT news and merely rebroadcasts from their site. Responses posted here are not monitored.

    -------------------------------------------------

    Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
    .
    Healthcare security & privacy posts not related to IT or infosec are at @HIPAABot . Even so, they mix in some infosec with the legal & regulatory information..
    .
    -------------------------------------------------

    #healthcare #healthtech #healthcaretech #healthtechnology #medgadget #medicine #doctor

    1 Reply Last reply
    1
    0
    • #medicineT #medicine shared this topic
    Reply
    • Reply as topic
    Log in to reply
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes


    • Login

    • Don't have an account? Register

    • Login or register to search.
    Powered by NodeBB Contributors
    • First post
      Last post
    0
    • Categories
    • Recent
    • Tags
    • Popular
    • World
    • Users
    • Groups